The strategic timing

The window is open now, before the picture changes.

In April 2026, Health Minister Carroll MacNeill commissioned Professor Shane Allwright (Trinity College Dublin) to formally review Ireland's Medical Cannabis Access Programme - including widening eligibility. The review's outcome will define the next 5 years. Whoever entrenches as the named supplier in AI answers, prescriber resources, and patient education before the review lands, holds the territory.

Five years, captured in four numbers

The case for a review.

Years MCAP has been live

Patients ever approved

Consultants who ever applied

Approved products on MCAP register

Source: Business of Cannabis, Cannabis Health News, gov.ie. The numbers tell their own story: scheme demand is constrained, prescriber adoption is constrained, the supplier set is small. Either MCAP expands or it doesn't survive in its current shape.

Two scenarios

How the review reshapes the market.

Today (the gated market)

Three indications. ~74 patients ever approved. 22 prescribers ever applied. Marketing pressure is low because the market is small. Any operational gain compounds directly into served-demand.

Strategic posture: serve the captive demand cleanly. Build the entity, schema, prescriber-resource layer while scrutiny is low and the field is empty.

Post-review (if expanded)

Wider indications - chronic pain, anxiety, sleep disorders are all candidates. New entrant suppliers will compete for AI-citation territory and prescriber mindshare. Patient demand floods the system.

Strategic posture: whoever owns condition-led content, HCP resources, and entity authority by then, holds the citation territory. Operations modules let Oleo scale into demand without doubling headcount.

The asymmetric bet: the operational and visibility work makes Oleo more valuable in BOTH scenarios. If MCAP narrows, ops automation extends runway. If MCAP expands, ops automation lets Oleo scale into demand without scaling cost.

What's in the review

What Allwright + the Department of Health are looking at.

Eligibility expansion - currently three indications, possibly widening to chronic pain, anxiety, sleep disorders, paediatric autism behavioural therapy
Supplier authorisation pathway - whether the HPRA process should be streamlined or restricted
Prescriber pathway - what's blocking the 22-consultants-ever number from growing
Reimbursement model - HSE coverage rules, patient out-of-pocket caps
Ministerial Licence pathway - whether to keep, restrict, or expand the parallel route
Patient pathway and waiting times - the user-side experience

Outcome timing is unclear but commentary in trade press suggests recommendations may surface late 2026 / early 2027.